{"id":{"repo_id":"ajou","oai_identifier":"oai:repository.ajou.ac.kr:201003/13073"},"canonical_url":"https://search.dev.ndltd.org/etd/ajou/oai:repository.ajou.ac.kr:201003/13073","repository":{"repo_id":"ajou","name":"Ajou University","base_url":"http://repository.ajou.ac.kr/oai/request"},"display":{"title":"Relation between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer","abstract":"PURPOSE: BRAFV600E mutation and F-18 fluorodeoxyglucose (FDG) uptake are potential prognostic factors of papillary thyroid cancer (PTC). This study was performed to investigate the relationship between the BRAFV600E mutation and F-18 FDG uptake in PTC. MATERIALS AND METHODS: We retrospectively included 169 PTC patients who underwent F-18 FDG positron emission tomography/computed tomography (PET/CT) before thyroidectomy from May 2009 to August 2012. Subjects were classified into overt PTC (> 1 cm, n = 76) and papillary thyroid microcarcinoma (PTMC, n = 93) groups. Univariate and multivariate analyses were performed to assess the relationship between maximum standardized uptake value (SUVmax) of the primary tumor and clinicopathologic variables. RESULTS: The BRAFV600E mutation was detected in 82.2% (139/169). In all subjects, the BRAFV600E mutation and tumor size were independently related to SUVmax by multivariate analysis (P = 0.048 and P < 0.001, respectively). SUVmax was significantly higher in tumors with the BRAFV600E mutation than in those with wild-type BRAF (9.4 ± 10.9 vs. 5.0 ± 4.1, P < 0.001). Similarly, in overt PTC group, the BRAFV600E mutation and tumor size were independently correlated with SUVmax (P = 0.032 and P = 0.001, respectively). By contrast, in PTMC group, only tumor size was significantly associated with SUVmax (P = 0.010). CONCLUSIONS: The presence of the BRAFV600E mutation is independently associated with high F-18 FDG uptake on preoperative PET/CT in patients with overt PTC, but this relationship was not evident in PTMC. This study provides a better understanding of the relationship between F-18 FDG uptake and BRAFV600E mutation in patients with PTC.","abstract_html":"PURPOSE: BRAFV600E mutation and F-18 fluorodeoxyglucose (FDG) uptake are potential prognostic factors of papillary thyroid cancer (PTC). This study was performed to investigate the relationship between the BRAFV600E mutation and F-18 FDG uptake in PTC. MATERIALS AND METHODS: We retrospectively included 169 PTC patients who underwent F-18 FDG positron emission tomography/computed tomography (PET/CT) before thyroidectomy from May 2009 to August 2012. Subjects were classified into overt PTC (&gt; 1 cm, n = 76) and papillary thyroid microcarcinoma (PTMC, n = 93) groups. Univariate and multivariate analyses were performed to assess the relationship between maximum standardized uptake value (SUVmax) of the primary tumor and clinicopathologic variables. RESULTS: The BRAFV600E mutation was detected in 82.2% (139/169). In all subjects, the BRAFV600E mutation and tumor size were independently related to SUVmax by multivariate analysis (P = 0.048 and P &lt; 0.001, respectively). SUVmax was significantly higher in tumors with the BRAFV600E mutation than in those with wild-type BRAF (9.4 ± 10.9 vs. 5.0 ± 4.1, P &lt; 0.001). Similarly, in overt PTC group, the BRAFV600E mutation and tumor size were independently correlated with SUVmax (P = 0.032 and P = 0.001, respectively). By contrast, in PTMC group, only tumor size was significantly associated with SUVmax (P = 0.010). CONCLUSIONS: The presence of the BRAFV600E mutation is independently associated with high F-18 FDG uptake on preoperative PET/CT in patients with overt PTC, but this relationship was not evident in PTMC. This study provides a better understanding of the relationship between F-18 FDG uptake and BRAFV600E mutation in patients with PTC.","abstract_has_math":false,"creators":["윤, 석호"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["윤, 준기","대학원 의학과","200724298"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-11-30T23:38:48Z","date_published":"2016-11-30T23:38:48Z","updated_at":"2026-07-24T00:51:53Z","subjects":["유두상 갑상선암","BRAFV600E mutation","F-18 FDG","PET/CT","SUVmax"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000022693","000000022693"],"render_values":[{"text":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000022693","href":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000022693","code":true},{"text":"000000022693","href":null,"code":true}]}]},"links":{"outbound_url":"http://repository.ajou.ac.kr/handle/201003/13073","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["윤, 준기","대학원 의학과","200724298","윤, 석호"]},{"key":"dc:creator","label":"Author","values":["윤, 석호"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2016-11-30T23:38:48Z","2016"]},{"key":"dc:type","label":"Dc Type","values":["Thesis","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["유두상 갑상선암","BRAFV600E mutation","F-18 FDG","PET/CT","SUVmax"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://repository.ajou.ac.kr/handle/201003/13073","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000022693","000000022693"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["PURPOSE: BRAFV600E mutation and F-18 fluorodeoxyglucose (FDG) uptake are potential prognostic factors of papillary thyroid cancer (PTC). This study was performed to investigate the relationship between the BRAFV600E mutation and F-18 FDG uptake in PTC. MATERIALS AND METHODS: We retrospectively included 169 PTC patients who underwent F-18 FDG positron emission tomography/computed tomography (PET/CT) before thyroidectomy from May 2009 to August 2012. Subjects were classified into overt PTC (> 1 cm, n = 76) and papillary thyroid microcarcinoma (PTMC, n = 93) groups. Univariate and multivariate analyses were performed to assess the relationship between maximum standardized uptake value (SUVmax) of the primary tumor and clinicopathologic variables. RESULTS: The BRAFV600E mutation was detected in 82.2% (139/169). In all subjects, the BRAFV600E mutation and tumor size were independently related to SUVmax by multivariate analysis (P = 0.048 and P < 0.001, respectively). SUVmax was significantly higher in tumors with the BRAFV600E mutation than in those with wild-type BRAF (9.4 ± 10.9 vs. 5.0 ± 4.1, P < 0.001). Similarly, in overt PTC group, the BRAFV600E mutation and tumor size were independently correlated with SUVmax (P = 0.032 and P = 0.001, respectively). By contrast, in PTMC group, only tumor size was significantly associated with SUVmax (P = 0.010). CONCLUSIONS: The presence of the BRAFV600E mutation is independently associated with high F-18 FDG uptake on preoperative PET/CT in patients with overt PTC, but this relationship was not evident in PTMC. This study provides a better understanding of the relationship between F-18 FDG uptake and BRAFV600E mutation in patients with PTC.","목적: BRAFV600E mutation과 F-18 fluorodeoxyglucose (FDG) 섭취는 유두상 갑상선암 (papillary thyroid cancer, PTC)의 잠재적인 예후인자이다. 본 연구는 유두상 감상선암에서 BRAFV600E mutation과 F-18 FDG 섭취의 연관성을 조사하기 위하여 시행되었다. 방법: 2009년 9월부터 2012년 8월까지 갑상선 전절제술을 받기 전에 positron emission tomography/computed tomography (PET/CT)를 시행받은 169명의 갑상선 유두상암 환자를 대상으로 후향적인 연구를 시행하였다. 대상자는 over PTC (> 1 cm, n = 76)와 papillary thyroid microcarcinoma (PTMC, n = 93)의 두 집단으로 분류하였다. 원발성 종양의 maximum standardized uptake value (SUVmax)와 임상적, 병리학적 변수들의 관계를 조사하기 위하여 단변량 분석과 다변량 분석을 시행하였다. 결과: BRAFV600E mutation은 82.2% (139/169)의 환자에서 발견되었다. 다변량 분석상 모든 대상자들에서 BRAFV600E mutation (P = 0.048)과 종양 크기 (P < 0.001)는 독립적으로 SUVmax와 유의한 연관성을 보였다. SUVmax는 wild-type BRAF인 종양에서보다 BRAFV600E mutation인 종양에서 유의하게 높았다 (9.4 ± 10.9 vs. 5.0 ± 4.1, P < 0.001). Overt PTC 집단에서 BRAFV600E mutation (P = 0.032)과 종양 크기 (P = 0.001)는 독립적으로 SUVmax와 유의한 연관성을 보였다. 그러나 PTMC 집단에서는 종양 크기만이 SUVmax와 유의한 연관성을 보였다 (P = 0.010). 결론: 크기가 1 cm보다 큰 유두상 갑상선암에서 BRAFV600E mutation의 존재는 수술 전 PET/CT상 높은 F-18 FDG 섭취와 독립적으로 유의한 연관성을 보였으나, 1 cm보다 작은 유두상 갑상선암에서는 유의한 연관성을 보이지 않았다. 본 연구는 유두상 갑상선암 환자에서 BRAFV600E mutation과 F-18 FDG 섭취의 연관성에 대한 증거를 제시하였다.","Ⅰ. INTRODUCTION 1 Ⅱ. MATERIALS AND METHODS 3 A. Patients 3 B. F-18 FDG PET/CT and Image Analysis 3 C. BRAFV600E Mutation Analysis 4 D. Statistical Analysis 5 Ⅲ. RESULTS 6 A. Patients’ Characteristics 6 B. Relationships between SUVmax and Clinicopathologic Variables in All Patients with PTC 6 C. Relationships between SUVmax and Clinicopathologic Variables in All Patients with Overt PTC 7 D. Relationships between SUVmax and Clinicopathologic Variables in All Patients with PTMC 8 Ⅳ. DISCUSSION 13 Ⅴ. CONCLUSION 17 REFERENCES 18 국문요약 23","Doctor"]},{"key":"dc:title","label":"Title","values":["Relation between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer","유두상 갑상선암에서 PET/CT의 F-18 FDG 섭취와 BRAFV600E mutation의 연관성"]}]}],"canonical_facts":{"dc:contributor":["윤, 준기","대학원 의학과","200724298","윤, 석호"],"dc:creator":["윤, 석호"],"dc:date":["2016-11-30T23:38:48Z","2016"],"dc:description":["PURPOSE: BRAFV600E mutation and F-18 fluorodeoxyglucose (FDG) uptake are potential prognostic factors of papillary thyroid cancer (PTC). This study was performed to investigate the relationship between the BRAFV600E mutation and F-18 FDG uptake in PTC. MATERIALS AND METHODS: We retrospectively included 169 PTC patients who underwent F-18 FDG positron emission tomography/computed tomography (PET/CT) before thyroidectomy from May 2009 to August 2012. Subjects were classified into overt PTC (> 1 cm, n = 76) and papillary thyroid microcarcinoma (PTMC, n = 93) groups. Univariate and multivariate analyses were performed to assess the relationship between maximum standardized uptake value (SUVmax) of the primary tumor and clinicopathologic variables. RESULTS: The BRAFV600E mutation was detected in 82.2% (139/169). In all subjects, the BRAFV600E mutation and tumor size were independently related to SUVmax by multivariate analysis (P = 0.048 and P < 0.001, respectively). SUVmax was significantly higher in tumors with the BRAFV600E mutation than in those with wild-type BRAF (9.4 ± 10.9 vs. 5.0 ± 4.1, P < 0.001). Similarly, in overt PTC group, the BRAFV600E mutation and tumor size were independently correlated with SUVmax (P = 0.032 and P = 0.001, respectively). By contrast, in PTMC group, only tumor size was significantly associated with SUVmax (P = 0.010). CONCLUSIONS: The presence of the BRAFV600E mutation is independently associated with high F-18 FDG uptake on preoperative PET/CT in patients with overt PTC, but this relationship was not evident in PTMC. This study provides a better understanding of the relationship between F-18 FDG uptake and BRAFV600E mutation in patients with PTC.","목적: BRAFV600E mutation과 F-18 fluorodeoxyglucose (FDG) 섭취는 유두상 갑상선암 (papillary thyroid cancer, PTC)의 잠재적인 예후인자이다. 본 연구는 유두상 감상선암에서 BRAFV600E mutation과 F-18 FDG 섭취의 연관성을 조사하기 위하여 시행되었다. 방법: 2009년 9월부터 2012년 8월까지 갑상선 전절제술을 받기 전에 positron emission tomography/computed tomography (PET/CT)를 시행받은 169명의 갑상선 유두상암 환자를 대상으로 후향적인 연구를 시행하였다. 대상자는 over PTC (> 1 cm, n = 76)와 papillary thyroid microcarcinoma (PTMC, n = 93)의 두 집단으로 분류하였다. 원발성 종양의 maximum standardized uptake value (SUVmax)와 임상적, 병리학적 변수들의 관계를 조사하기 위하여 단변량 분석과 다변량 분석을 시행하였다. 결과: BRAFV600E mutation은 82.2% (139/169)의 환자에서 발견되었다. 다변량 분석상 모든 대상자들에서 BRAFV600E mutation (P = 0.048)과 종양 크기 (P < 0.001)는 독립적으로 SUVmax와 유의한 연관성을 보였다. SUVmax는 wild-type BRAF인 종양에서보다 BRAFV600E mutation인 종양에서 유의하게 높았다 (9.4 ± 10.9 vs. 5.0 ± 4.1, P < 0.001). Overt PTC 집단에서 BRAFV600E mutation (P = 0.032)과 종양 크기 (P = 0.001)는 독립적으로 SUVmax와 유의한 연관성을 보였다. 그러나 PTMC 집단에서는 종양 크기만이 SUVmax와 유의한 연관성을 보였다 (P = 0.010). 결론: 크기가 1 cm보다 큰 유두상 갑상선암에서 BRAFV600E mutation의 존재는 수술 전 PET/CT상 높은 F-18 FDG 섭취와 독립적으로 유의한 연관성을 보였으나, 1 cm보다 작은 유두상 갑상선암에서는 유의한 연관성을 보이지 않았다. 본 연구는 유두상 갑상선암 환자에서 BRAFV600E mutation과 F-18 FDG 섭취의 연관성에 대한 증거를 제시하였다.","Ⅰ. INTRODUCTION 1 Ⅱ. MATERIALS AND METHODS 3 A. Patients 3 B. F-18 FDG PET/CT and Image Analysis 3 C. BRAFV600E Mutation Analysis 4 D. Statistical Analysis 5 Ⅲ. RESULTS 6 A. Patients’ Characteristics 6 B. Relationships between SUVmax and Clinicopathologic Variables in All Patients with PTC 6 C. Relationships between SUVmax and Clinicopathologic Variables in All Patients with Overt PTC 7 D. Relationships between SUVmax and Clinicopathologic Variables in All Patients with PTMC 8 Ⅳ. DISCUSSION 13 Ⅴ. CONCLUSION 17 REFERENCES 18 국문요약 23","Doctor"],"dc:identifier":["http://repository.ajou.ac.kr/handle/201003/13073","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000022693","000000022693"],"dc:language":["en"],"dc:subject":["유두상 갑상선암","BRAFV600E mutation","F-18 FDG","PET/CT","SUVmax"],"dc:title":["Relation between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer","유두상 갑상선암에서 PET/CT의 F-18 FDG 섭취와 BRAFV600E mutation의 연관성"],"dc:type":["Thesis","Theses"]},"updated_at":"2026-07-24T00:51:53Z"}